ELOX
Eloxx Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing small-molecule drugs that coax the body's protein-building machinery to "read through" genetic errors called nonsense mutations, which cause rare diseases like Alport syndrome. Its lead investigational drug, exaluren, aims to restore full-length functional proteins in patients with these conditions. Founded in 2013 by two scientists, the company went public in 2017 through a reverse merger with Sevion Therapeutics, and its name echoes the "ELX" prefix of its drug compounds.
CUSIP: 817208507HealthcareUS1 holder
Total Value
$67.0K
Total Shares
20.0K
Net Share Change
+10.0K
Activity
1 buying
Investor
Value
Shares
Weight
Change
